IGF-1 LR3 1mg — Anabolic Growth Factor

Protocol

Reconstitution & Usage Protocol

Important: Only chill the water for 3 minutes before reconstituting the peptide. Do not prepare with very cold water, as it can freeze, lose potency, or be damaged.

1Reconstitution

Materials: 1 vial of IGF-1 LR3 1 mg · 1 vial of bacteriostatic water · U-100 insulin syringe · alcohol wipes.

Bring the vial to temperature for 10–15 minutes at room temperature.
Disinfect the rubber caps with an alcohol wipe.
Draw 2 mL of bacteriostatic water (200 IU in an insulin syringe or 1 fill of a 3 mL syringe).
Inject the water slowly down the inner wall of the vial. IGF-1 LR3 is extremely fragile — a slow stream is mandatory, never directly onto the powder.
Do not shake. Swirl very gently for 30 seconds until the solution is clear.

Label with the date and refrigerate immediately (2–8 °C). Stable for 14–21 days (prompt use recommended).

2Concentration & Dosing

Reconstituting 1 mg (1000 mcg) in 2 mL → 0.5 mg/mL = 5 mcg per IU.

Target dose	Units	Volume
50 mcg (low)	10 IU	0.10 mL
75 mcg (standard)	15 IU	0.15 mL
100 mcg (high)	20 IU	0.20 mL

Universal formula: IU = (dose in mcg ÷ 5)

3Application

Route

Subcutaneous (systemic effect) or localized intramuscular into the target muscle (site effect).

Frequency

Once a day, preferably post-workout with carbohydrates to maximize muscular absorption.

Cycle

4 weeks maximum → mandatory 4-week rest (IGF-1 receptors downregulate with prolonged use).

Start: begin with 50 mcg/day for the first 2 weeks to assess tolerance and glycemic response.
Clinical attention: monitor capillary blood glucose — IGF-1 can cause mild hypoglycemia. Keep fast-acting carbohydrates available.
Before applying: let the drawn dose lose its chill (only the amount to be injected) — hold the syringe in your hand for 2–3 minutes.
After applying: gentle massage of the area for ~40 seconds to disperse the peptide and improve absorption.

Importante: Solo poner a enfriar el agua 3 minutos antes de reconstituir el péptido. No preparar con agua muy fría, porque se puede congelar, perder efecto o dañarse.

1Reconstitución

Materiales: 1 vial de IGF-1 LR3 1 mg · 1 vial de agua bacteriostática · jeringa de insulina U-100 · toallitas de alcohol.

Atemperar el vial 10–15 minutos a temperatura ambiente.
Desinfectar las tapas de goma con toallita de alcohol.
Cargar 2 mL de agua bacteriostática (200 UI en jeringa de insulina o 1 carga de jeringa de 3 mL).
Inyectar el agua lentamente por la pared interior del vial. IGF-1 LR3 es extremadamente frágil — chorro lento obligatorio, nunca directo sobre el polvo.
No agitar. Girar con mucha suavidad 30 segundos hasta solución transparente.

Etiquetar con fecha y refrigerar inmediatamente (2–8 °C). Estable 14–21 días (uso rápido recomendado).

2Concentración y dosis

Reconstituyendo 1 mg (1000 mcg) en 2 mL → 0,5 mg/mL = 5 mcg por UI.

Dosis objetivo	Unidades	Volumen
50 mcg (baja)	10 UI	0,10 mL
75 mcg (estándar)	15 UI	0,15 mL
100 mcg (alta)	20 UI	0,20 mL

Fórmula universal: UI = (dosis en mcg ÷ 5)

3Aplicación

Vía

Subcutánea (efecto sistémico) o intramuscular localizada en el músculo objetivo (efecto de sitio).

Frecuencia

1 vez al día, preferiblemente post-entrenamiento con carbohidratos para maximizar absorción muscular.

Ciclo

4 semanas máximo → descanso obligatorio de 4 semanas (los receptores IGF-1 se regulan a la baja con uso prolongado).

Inicio: comenzar con 50 mcg/día las primeras 2 semanas para evaluar tolerancia y respuesta glucémica.
Atención clínica: vigilar glucemia capilar — IGF-1 puede causar hipoglucemia leve. Tener carbohidratos rápidos disponibles.
Antes de aplicar: dejar que la dosis cargada pierda el frío (solo la cantidad a inyectar) — sostener la jeringa en la mano 2–3 minutos.
Después de aplicar: masaje suave en la zona durante ~40 segundos para dispersar el péptido y mejorar absorción.

Important : Ne mettre l'eau à refroidir que 3 minutes avant de reconstituer le peptide. Ne pas préparer avec de l'eau très froide, car il peut geler, perdre son effet ou être endommagé.

1Reconstitution

Matériel : 1 flacon d'IGF-1 LR3 1 mg · 1 flacon d'eau bactériostatique · seringue à insuline U-100 · lingettes alcoolisées.

Laisser le flacon revenir à température ambiante pendant 10–15 minutes.
Désinfecter les bouchons en caoutchouc avec une lingette alcoolisée.
Prélever 2 mL d'eau bactériostatique (200 UI dans une seringue à insuline ou 1 remplissage d'une seringue de 3 mL).
Injecter l'eau lentement le long de la paroi intérieure du flacon. L'IGF-1 LR3 est extrêmement fragile — un jet lent est obligatoire, jamais directement sur la poudre.
Ne pas secouer. Faire tourner très doucement pendant 30 secondes jusqu'à obtention d'une solution transparente.

Étiqueter avec la date et réfrigérer immédiatement (2–8 °C). Stable 14–21 jours (utilisation rapide recommandée).

2Concentration et dosage

En reconstituant 1 mg (1000 mcg) dans 2 mL → 0,5 mg/mL = 5 mcg par UI.

Dose cible	Unités	Volume
50 mcg (faible)	10 UI	0,10 mL
75 mcg (standard)	15 UI	0,15 mL
100 mcg (élevée)	20 UI	0,20 mL

Formule universelle : UI = (dose en mcg ÷ 5)

3Application

Voie

Sous-cutanée (effet systémique) ou intramusculaire localisée dans le muscle ciblé (effet de site).

Fréquence

1 fois par jour, de préférence après l'entraînement avec des glucides pour maximiser l'absorption musculaire.

Cycle

4 semaines maximum → repos obligatoire de 4 semaines (les récepteurs IGF-1 se régulent à la baisse en cas d'utilisation prolongée).

Début : commencer par 50 mcg/jour les 2 premières semaines pour évaluer la tolérance et la réponse glycémique.
Attention clinique : surveiller la glycémie capillaire — l'IGF-1 peut provoquer une légère hypoglycémie. Avoir des glucides rapides à disposition.
Avant l'application : laisser la dose prélevée perdre son froid (uniquement la quantité à injecter) — tenir la seringue dans la main pendant 2–3 minutes.
Après l'application : massage doux de la zone pendant ~40 secondes pour disperser le peptide et améliorer l'absorption.

Open dosage calculator →

Research Highlights

Research models attribute IGF-1 LR3's extended half-life of approximately 20–30 hours, versus roughly 15 minutes for native IGF-1, to reduced binding to IGF-binding proteins that keeps more peptide bioavailable.
Study data describe IGF-1 receptor activation as driving protein synthesis and muscle hyperplasia, the formation of new muscle fibers, distinguishing it from hypertrophy-only signaling pathways.
Research literature notes the insulin-like signaling of IGF-1 can lower blood glucose, supporting the emphasis on glycemic monitoring and a capped 4-week framework to limit receptor downregulation.

FAQ

Frequently Asked Questions

What makes IGF-1 LR3 different from native IGF-1 in research models?

IGF-1 LR3 (Long R3) is a modified analog whose extended half-life of approximately 20–30 hours far exceeds the roughly 15 minutes of native IGF-1, prolonging receptor signaling in study models. An arginine substitution at position 3 reduces binding to IGF-binding proteins, leaving more peptide bioavailable. It is supplied strictly for in-vitro and laboratory research use.

How is IGF-1 LR3 reconstituted and what concentration results?

Reconstituting the 1 mg (1000 mcg) vial with 2 mL of bacteriostatic water yields a 0.5 mg/mL solution, equal to 5 mcg per IU on a U-100 insulin syringe. The peptide is extremely fragile, so the water must be directed slowly down the vial wall and the solution swirled gently for 30 seconds rather than shaken. These figures describe laboratory handling only.

What dosing and cycle framework appears in IGF-1 LR3 research protocols?

Study references typically describe a once-daily schedule, often beginning at 50 mcg/day for the first 2 weeks to gauge tolerance, with documented ranges of 50–100 mcg (10–20 IU). A 4-week-maximum framework followed by a mandatory 4-week rest reflects IGF-1 receptor downregulation under prolonged exposure. These figures describe the literature only and are not human-use instructions.

Why is glycemic monitoring emphasized in IGF-1 LR3 study handling?

Because IGF-1 shares structural and signaling features with insulin, study notes flag a tendency toward mild hypoglycemia, so capillary blood glucose monitoring and fast-acting carbohydrates are emphasized in research handling. Subcutaneous administration produces a systemic effect, whereas localized intramuscular injection into a target muscle produces a site effect. This compound is for laboratory research use only.

Related Compounds

← Previous

TB-500 + BPC-157 20mg

Next →

GHRP-6

← Back to full catalog